5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
India
The Injectable Drug Delivery Devices Market is segmented by Device Type (Conventional Drug Delivery Devices and Self-injectable Drug Delivery Devices), Therapeutic Application, and Geography.
Study Period:
2017-2025
Base Year:
2020
Fastest Growing Market:
Asia Pacific
Largest Market:
North America
CAGR:
11.5 %
The injectable drug delivery devices market is expected to show rapid growth due to the growing burden of chronic diseases, benefits, and convenience, leading to increased demand for self injectors and growth of the biologics market, leading to increased demand for injectors.
The growing burden of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes. It has been observed that most deaths by chronic diseases can be attributed to cardiovascular diseases, obesity, and diabetes. This is expected to affect the emerging countries the most, as population growth is found to be the most significant factor in developing areas.
A major number of drugs and therapies that address these chronic ailments are now found to be available. However, the use of syringes in the management of any chronic ailment is inevitable. Syringes can either be a part of sample collection during diagnosis or treatment regimen, like osteoarthritis. Consequently, the rise in the prevalence of chronic diseases is expected the drive the growth of the market studied.
Furthermore, technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market are some of the other factors propelling the growth of the market.
As per the scope of the report, the injectable devices are being used to administer drugs either intravenously, through intramuscular or subcutaneously, and are considered as injectable drug delivery devices. The injectable method is the most frequently used method for drugs that have poor oral bioavailability, targeted drug delivery systems, and delivery of drugs at the site of action. Injectable drug delivery is used in conditions, such as hormonal imbalance, cystic fibrosis, autoimmune diseases, pain, Wilson’s disease, hemophilia, hepatitis C, and ribose-5-phosphate isomerase deficiency.
By Devices Type | |||||||
Conventional Drug Delivery Devices | |||||||
|
By Therapeutic Application | |
Cardiovascular Disease | |
Diabetes | |
Oncology | |
Autoimmune Disorders | |
Hepatitis | |
Other Therapeutic Applications |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Report scope can be customized per your requirements. Click here.
There have been boundless innovations and developments in self-injectable devices which is driving the growth of the market. The other major advantages associated with self-injectable devices are that they are found to be of convenient usage and low healthcare cost. These self-injectables were developed with the help of patient feedback, to provide the most adaptable devices, which have high precision of drug delivery, and are easy to use.
In addition to this, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. Nevertheless, the advantages of self-injectable injections and increasing awareness of self-administration have helped in driving the overall market studied, during the forecast period.
To understand key trends, Download Sample Report
North America has been found dominating the injectable drug delivery devices, due to the increasing aging population and the rising number of chronic diseases that may influence the usage of injectables. According to the National Cancer Institute, 2018, there were an estimated 1,735,350 new cases of cancer that were being diagnosed in the United States. Therefore, chemotherapy drugs are being delivered to these cancer patients through injectable devices. Hence, increasing prevalence of chronic diseases and the adoption of new technologies related to injectables in the United States may help in propelling the growth of the overall market.
There are also some of the other factors that include; the large pool of patient population, increasing healthcare expenditure, rising focus of various companies, increasing healthcare awareness, and increase in government funding. Hence, all these factors are found associated with the growth of the market.
To understand geography trends, Download Sample Report.
The companies present in the market are found focusing on product innovations, expansions, finding new markets, or innovating their core competency to expand their individual market shares. There are also innovations taking place in injectable drug delivery systems that are the trend for the global injectable drug delivery market.
1. INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Chronic Diseases
4.2.2 Benefits and Convenience in Self Injectors
4.2.3 Growth of the Biologics Market Leading to Increased Demand for Injectors
4.3 Market Restraints
4.3.1 Injuries and Infections Caused by Needles
4.3.2 Increasing Use of Alternative Delivery Methods
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Devices Type
5.1.1 Conventional Drug Delivery Devices
5.1.2 Advanced Drug Delivery Devices
5.1.2.1 Prefilled Syringes
5.1.2.2 Injectable Pens
5.1.2.3 Auto Injectors
5.1.2.4 Needle-free Injectors
5.1.2.5 Other Device Types
5.2 By Therapeutic Application
5.2.1 Cardiovascular Disease
5.2.2 Diabetes
5.2.3 Oncology
5.2.4 Autoimmune Disorders
5.2.5 Hepatitis
5.2.6 Other Therapeutic Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter International Inc.
6.1.2 Becton, Dickinson and Company
6.1.3 Eli Lilly and Company
6.1.4 Gerresheimer AG
6.1.5 Novo Nordisk A/S
6.1.6 Pfizer Inc.
6.1.7 Schott AG
6.1.8 Terumo Corporation
6.1.9 Teva Pharmaceutical Industries Ltd
6.1.10 West Pharmaceutical Services Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments